<DOC>
	<DOCNO>NCT02263859</DOCNO>
	<brief_summary>The purpose study evaluate benefit risk hypoglossal nerve stimulation ImThera Medical aura6000 System potential therapeutic option individual moderate severe OSA fail tolerate PAP .</brief_summary>
	<brief_title>Targeted Hypoglossal Neurostimulation Study # 3</brief_title>
	<detailed_description>The objective study evaluate safety effectiveness aura6000 System treatment moderate severe obstructive sleep apnea ( OSA ) individual fail tolerate positive airway pressure ( PAP ) therapy fail intolerant refuse indicate alternative OSA treatment ( oral appliance , positional device conventional sleep surgery ) . PAP failure define inability eliminate OSA ( AHI &gt; 20 despite PAP usage ) PAP intolerance define : 1 ) inability use PAP ( great 5 night per week usage ; usage define great 4 hour use per night ) ; 2 ) unwillingness use PAP ( example , patient return PAP system attempt use ) . The result study anticipated provide reasonable assurance safety effectiveness aura6000 System use intend support application FDA Premarket Approval system .</detailed_description>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>Age &gt; 18 year Individual fail tolerate PAP therapy Has fail refuse alternative OSA treatment ( e.g.surgery , oral appliance , behavioral treatment ) AHI ≥ 20 ( Moderate severe OSA ) Exclusion Critera : Implanted another active implantable device Body mass index ( BMI ) ≥ 35 kg/m²</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Obstructive Sleep Apnea</keyword>
</DOC>